Immuno-Oncology is a scientific field that involves developing therapeutics that take advantage of the body's immune system to fight cancer. Champions Oncology has developed innovative platforms that give Immuno-oncology researchers the tools they need to test their therapeutic drug's mechanism of action.
The Autologous TIL platform is an ex vivo 3D co-culture platform developed to interrogate the responses of your Immuno-Oncology drugs with a tumor-specific microenvironment using PDX-O (patient-derived xenograft organoids) collected with matched, autologous TIL samples.
The Autologous AML platform is an ex vivo co-culture platform developed and optimized to interrogate the responses of your immuno-oncology drugs in only 4 days using primary patient-matched specimens.